Literature DB >> 11570577

The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma.

J Zhou1, Z Y Tang, J Fan, Z Q Wu, Y Ji, S L Ye.   

Abstract

PURPOSE: To study the relationship between thrombomodulin (TM) plasma levels and the formation of portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma (HCC).
METHODS: Pre- and-postoperative plasma TM levels of 45 patients with HCC and six patients with benign liver-occupying lesion were measured by enzyme-linked immunosorbent assay (ELISA), and the expression of TM in human HCC tissues was determined by immunohistochemistry assay.
RESULTS: The preoperative plasma TM level of patients with HCC (10.2+/-5.7 ng/ml) was significantly higher than that of those patients with benign liver-occupying lesion (6.1+/-2.2 ng/ml) and that of normal controls (5.7+/-1.0 ng/ml), respectively (P<0.05). The postoperative TM level of 40 patients with HCC whose tumors had been removed decreased significantly than the preoperative TM level (10.8+/-5.3 ng/ml versus 7.6+/-4.2 ng/ ml, P < 0.05), whereas there was no significant difference between the preoperative and postoperative TM level of six patients with benign liver-occupying lesion (6.1+/-2.2 ng/ml versus 5.9+/-1.8 ng/ml, P>0.05). The preoperative plasma TM level of patients with single HCC (11.5+/-5.9 ng/ml) or no PVTT (11.4+/-5.6 ng/ml) was significantly higher than that of those patients with multiple HCC (8.1+/-4.6 ng/ml) or PVTT (6.9+/-4.5 ng/ ml), respectively (P<0.05). The preoperative plasma TM level of the patients with HCC tissue that stained positive for TM was significantly higher than those with tissue that stained negative for TM (12.2+/-6.5 ng/ ml versus 8.7+/-4.6 ng/ml, P<0.05). The postoperative plasma TM level showed no difference between the patients with HCC tissue stained positive and negative for TM (8.3+/-4.1 ng/ml versus 7.6+/-4.4 ng/ml, P>0.05). There was also no significant difference between the plasma TM level and other clinicopathological futures.
CONCLUSIONS: Plasma TM increases in patients with HCC and can be a biomarker of the formation of PVTT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11570577     DOI: 10.1007/s004320100237

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  3 in total

1.  Foxp3+ regulatory T cells and the formation of portal vein tumour thrombus in patients with hepatocellular carcinoma.

Authors:  Shun Li Shen; Li Jian Liang; Bao Gang Peng; Qiang He; Ming Kuang; Jia Ming Lai
Journal:  Can J Surg       Date:  2011-04       Impact factor: 2.089

Review 2.  A decade's studies on metastasis of hepatocellular carcinoma.

Authors:  Zhao-You Tang; Sheng-Long Ye; Yin-Kun Liu; Lun-Xiu Qin; Hui-Chuan Sun; Qin-Hai Ye; Lu Wang; Jian Zhou; Shuang-Jian Qiu; Yan Li; Xue-Ning Ji; Hu Liu; Jing-Ling Xia; Zhi-Quan Wu; Jia Fan; Zeng-Chen Ma; Xin-Da Zhou; Zhi-Ying Lin; Kang-Da Liu
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-18       Impact factor: 4.553

3.  Hypercoagulable states in patients with hepatocellular carcinoma.

Authors:  Demetrios N Samonakis; Ioannis E Koutroubakis; Aekaterini Sfiridaki; Niki Malliaraki; Pavlos Antoniou; John Romanos; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.